Noemi Horvath

North Terrace
Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma.

Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma.

Journal: Leukemia

Published: June 05, 2024

Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.

Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 06, 2024

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.

Journal: Blood advances

Published: December 29, 2023

Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.

Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.

Journal: Haematologica

Published: September 19, 2023

Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients.

Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients.

Journal: Haematologica

Published: June 25, 2023

Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.

Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.

Journal: British journal of haematology

Published: January 25, 2023

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma.

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma.

Journal: Blood cancer journal

Published: December 06, 2022

Lenalidomide Desensitization for Delayed Cutaneous Reaction: A Case Series and Review of the Literature.

Lenalidomide Desensitization for Delayed Cutaneous Reaction: A Case Series and Review of the Literature.

Journal: The journal of allergy and clinical immunology. In practice

Published: October 31, 2022

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.

Journal: Blood

Published: September 06, 2022

Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia.

Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia.

Journal: Internal medicine journal

Published: April 29, 2021

Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometry-based proteomics in an Australian cohort.

Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometry-based proteomics in an Australian cohort.

Journal: Internal medicine journal

Published: May 19, 2020

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.

Journal: Journal of hematology & oncology

Published: April 08, 2020

Showing 1-12 of 27

Last Updated: 09/26/2026